Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Metadata
Title
A population-based study of the impact of delaying radiotherapy after conservative surgery for breast cancer
Authors
Nicole Hébert-croteau
Carolyn R. Freeman
Jean Latreille
Michèle Rivard
Jacques Brisson
Publication date
01-11-2004
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 2/2004
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-004-0594-7

Other articles of this Issue 2/2004

Breast Cancer Research and Treatment 2/2004 Go to the issue

OriginalPaper

Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma

OriginalPaper

Response to fulvestrant in heavily pretreated postmenopausal women:a single-center experience

OriginalPaper

Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program

OriginalPaper

Distinct incidence patterns among in situ and invasive breast carcinomas,with possible etiologic implications

OriginalPaper

Racial disparities in female breast cancer in South Carolina: clinical evidence for a biological basis

OriginalPaper

Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits